Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19363801 | 0.98 | TLR8 (0.32) | TLR8CNR2CNR1CES2LPAR1 | |
| SCHEMBL19363951 | 0.98 | TLR8 (0.32) | TLR8CNR2CNR1CES2LPAR1 | |
| SCHEMBL19363812 | 0.98 | TLR8 (0.32) | TLR8CNR2CNR1CES2LPAR1 | |
| SCHEMBL21783862 | 0.95 | TLR8 (0.31) | TLR8 | |
| SCHEMBL22541458 | 0.95 | TLR8 (0.36) | TLR8 | |
| SCHEMBL20031361 | 0.92 | TLR8 (0.31) | TLR8 | |
| SCHEMBL22460324 | 0.91 | TLR8 (0.34) | TLR8 | |
| SCHEMBL18474327 | 0.88 | TLR8 (0.34) | TLR8 | |
| SCHEMBL18523068 | 0.84 | CNR2 (0.37) | TLR8CNR2CNR1 | |
| SCHEMBL23583995 | 0.83 | NPC1 (0.38) | TLR8CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | TLR8 4387/4885CNR2 949/4885CNR1 770/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | TLR8 4387/4885CNR2 949/4885CNR1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.